Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma.

Fiche publication

Date publication

novembre 2025

Journal

Journal for immunotherapy of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr OREND Gertraud

Tous les auteurs :
de Sostoa J, Marinari E, Pedard M, Widmer V, Davanture S, Schaller K, Tissot S, De Palma M, Wolf B, Orend G, Dutoit V, Migliorini D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41188009

Résumé

Glioblastoma (GBM) is an aggressive brain tumor associated with poor outcome and limited treatment options. Chimeric antigen receptor (CAR) T cells targeting cell surface antigens were shown to induce tumor regression in patients with GBM, although efficacy was transient. To broaden the range of tumor-restricted antigens, we developed CAR T cells targeting Tenascin-C (TNC), a secreted extracellular matrix protein that is overexpressed in GBM and plays a critical role in tumor progression.